Phase 2 N=71 Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=118 Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Primary: Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population — 33.3 Percentage of participants
Phase 2 N=24 Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
Invasive Breast Carcinoma · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: RCB Status — 4; 6; 8; 6 Participants
Phase 2 N=18 Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
Androgen Receptor Positive · Estrogen Receptor Negative · HER2/Neu Negative
Primary: Response Rate (Complete Response or Partial Response) — 1; 1; 2; 12 Participants
Phase 2 N=24 Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Phase 2 N=90 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Prostate Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Phase 2 N=32 Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Breast Cancer
Primary: Clinical Benefit Rate of the Combination of Enzalutamide/ Fulvestrant — 7 Participants
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 2 N=48 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Breast Cancer
Primary: Median Progression Free Survival (PFS) — 7.2 months
Phase 2 N=35 Cabozantinib for Metastatic Triple Negative BrCa
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
Phase 2 N=136 Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
ER+ and AR+ Breast Cancer
Primary: Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects — 16; 15 participants
Phase 2 N=45 COMbination of Bipolar Androgen Therapy and Nivolumab
Castration-resistant Prostate Cancer · Metastatic Prostate Cancer · Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy + Nivolumab — 18 Participants
Phase 2 N=37 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Estrogen Receptor Negative · HER2/Neu Negative · Invasive Breast Carcinoma
Primary: Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6…
Phase 2 N=59 Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Advanced Epithelial Ovarian · Recurrent Epithelial Ovarian · Fallopian Tube
Primary: Overall Response Rate — 1.7 percentage of participants with response
Phase 2 N=50 BKM120 For Triple Negative Breast Cancer
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Phase 2 N=103 A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
HER2 Amplified · Advanced Breast Cancer · Human Epidermal Growth Factor Receptor 2 (HER2)
Primary: Clinical Benefit Rate (CBR) — 23.6 percentage of participants
Phase 2 N=10 LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 3 Participants
Phase 2 N=152 A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Breast Cancer
Primary: Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor Biopsies — 71.4; 72.9 Percent reduction
Phase 2 N=21 Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Phase 2 N=10 TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 1 Participants
Phase 3 N=579 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast Cancer
Primary: Cohort A: Progression-Free Survival (PFS) — 6.1; 7.4 months — p=0.9237
Phase 2 N=42 Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Breast Cancer
Primary: Phase Ib Primary Outcome: Proportion of Patients Who Experienced DLTs Attributable to Palbociclib, Tucatinib, or Both — 100; 65; 100 percentage of participants
Phase 1 N=35 Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 2 participants
Phase 2 N=17 Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
Invasive Breast Carcinoma · Triple-Negative Breast Carcinoma
Primary: RCB Status — 0; 1; 13; 3 participants
Phase 2 N=30 Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer
Breast Cancer Metastatic
Primary: Progression-free Survival (PFS) — 5 months
Phase 2 N=120 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) Determined by Clinical Palpation — 58.9; 53.8 percentage of participants
Phase 2 N=52 AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)
Breast Cancer
Primary: Number of Participants With Serious Adverse Events (SAEs) — 10 Participants
Phase 2 N=49 Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Malignant Neoplasm of Breast · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Estrogen Receptor Positive Breast Cancer
Primary: Progression Free Survival (PFS) Per RECIST 1.1 — 9.13 Months
Phase 1 N=12 Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients
Advanced Breast Cancer
Primary: Incidence Rate of DLT Within the First Two Cycles of LDE225 (Sonidegib) in Combination With Docetaxel — 0; 0; 0 Participants